This book chapter advances SDG #3 and #10 by reviewing the latest developments in the field of clinical diagnosis and pharmacotherapeutics have provided hope to ameliorate the behavioral changes and cognitive disturbances associated with the disease.

This book chapter advances SDG #3 and #10 by focusing on mouse models of Alzheimer’s disease (AD), especially the 5xFAD line.

This book chapter advances SDG #3 and #10 by outlining the pathophysiology associated with Alzheimer’s disease and provide an overview of the impact of exercise programs on cognition, physical functional abilities, behavioral, and psychological symptoms and quality of life.

This book chapter advances SDG #3 and #10 by introducing the basic foundation of aging, dementia and Alzheimer Disease, including clinical presentation, diagnosis and epidemiology.

This book chapter advances SDG #3 and #10 by focusing on an emblematic delayed-onset pathology often seen after traumatic brain injury—Alzheimer’s disease—and explain its relationship with chronic traumatic encephalopathy.

This book chapter advances SDG #3 and #10 by providing a brief outline of AD epidemiology, the definition of an AD biomarker, the classification and features of AD, and AD risk factors, followed by a description of the structure and content of each of the following chapters and their focus on specific types of AD biomarkers.

This book chapter advances SDG #3 and #10 by reviewing studies that showed treatments with multiple sessions of rTMS can influence cognition in people with neurodegenerative diseases. The chapter also considers novel therapeutic approaches based on the clinical use of rTMS.

This book chapter advances SDG #3 and #10 by reviewing the observed epidemiological links between normal and abnormal diurnal and seasonal rhythmicity, cognitive impairment, and ADRD. Then reviewing normal diurnal and seasonal rhythms of brain epigenetic modification and gene expression in model organisms. Finally, reviewing evidence for diurnal and seasonal rhythms of epigenetic modification and gene expression the human brain in aging, Alzheimer's disease, and other brain disorders.

This book chapter advances SDG 3 and 10 by presenting that (1) some of these depression scales do not correlate, suggesting that they assess different aspects of depression; (2) reports of depression in dementia vary based on depression in dementia scale used; and (3) severe memory impairment may impact the ability to assess depression in the patients using self-reports.

This book chapter advances SDG #3 and #10 by providing therapeutic strategies that can be employed in clinical trials for AD in DS will be discussed as well as their underlying scientific rationale.